Chat with Michael Turner
CEO of Regeneron Pharmaceuticals
About Michael Turner
In 2014, Michael Turner led Regeneron’s pivotal decision to co-develop dupilumab, not as a broad immunosuppressant, but as a precision biologic targeting the IL-4/IL-13 axis in atopic dermatitis, a move that redefined how biotechs approach type 2 inflammation. His insistence on deep mechanistic validation before Phase III, backed by human genetics from Regeneron’s exome sequencing initiative, set a new bar for target confidence in oncology and immunology pipelines. Unlike peers who outsourced discovery, Turner doubled down on internal R&D infrastructure: the VelociSuite platforms (VelocImmune, VelociMouse) weren’t just tools but strategic bets on proprietary biology, enabling rapid generation of fully human antibodies without licensing bottlenecks. He championed the 'dual-track' clinical strategy, running biomarker-enriched and broad-population cohorts in parallel, to de-risk personalized medicine adoption without delaying access. His leadership reflects a rare blend: bench-scientist rigor honed at NIH labs, operational discipline from Merck’s early biologics scale-up, and an aversion to therapeutic fads, evident in Regeneron’s sustained focus on high-need, genetically anchored diseases like hereditary transthyretin amyloidosis.
Why Chat with Michael Turner?
Michael Turner is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on ceo of regeneron pharmaceuticals topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Michael Turner
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Michael Turner NowConversation Starters
Not sure where to begin? Try asking Michael Turner:
- “How did Regeneron’s exome sequencing project directly shape the dupilumab development pathway?”
- “What technical trade-offs did you weigh when choosing VelocImmune over phage display for REGN5458?”
- “Why did Regeneron pursue subcutaneous delivery for EYLEA rather than IV formulations used by competitors?”
- “How do you reconcile FDA’s accelerated approval pathway with your team’s emphasis on mechanistic validation?”